SINGULAIR 5 MG 14 CHEWABLE TAB

* SINGULAIR (Montelukast, MSD) 5 mg Paediatric 14 Chewable Tablets.
* Indications: Singulair is indicated in adult and pediatric patients 6 months of age and older for the prophylaxis && chronic treatment
& & of asthma, including the prevention od day- and nighttime symptoms, th treatment of aspirin-sensitive asthmatic patients,
& & and the prevention of excercise-induced bronchoconstriction. Singulair is indicated for the relief of daytime and nighttime symptoms
& & of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older).
* Dosage && Administration:
& & – Singulair should be taken once daily. For asthma, the dose should be taken in the evening. For allegic rhinitis, the time of
& & administration may be individualized to suit patient needs.
& & – Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.
& & – Adults 15 years of age and older with asthma and/or seasonal allergic rhinitis: one 10-mg tablet daily.
& & – Pediatric patients 6 to 14 years of age with asthma and/or seasonal allergic rhinitis: 5-mg chewable tablet daily.
& & – Pediatric patients 2 to 5 years of age with asthma and/or seasonal allergic rhinitis: one 4-mg chewable tablet daily or one packet
& & of 4-mg oral granules daily.
& & – Pediatric patients 6 months to 2 years of age with asthma: one packet of 4-mg oral granules daily.
* To be dispensed by or on the prescription of physician.
* Store in a dry place, at temperature between 15-30 degrees C, protected from moisture && light.
* Produced by: Global Napi Pharmaceuticals (GNP) – Egypt.
& & Under license from: Merck && Co. Inc., Whitehouse Station, N.J., USA && its subsidiary in UK. (MSD)
& & Registered trademark of Merck && Co. Inc., Whitehouse Station, N.J., USA.